https://orcid.org/0000-0001-6689-0438
Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Matthew Matasar, Anthony Masaquel, Rodrigo S. Ho, Aino Launonen, Carmen D. Ng, Rongrong Wang, David Fox, Farah Hossain, Jia Li & John M. Burke. (2023) US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. Journal of Medical Economics 26:1, pages 1134-1144.
Read now
Read now
Jingbo Zhang, Yiwei Guo, Huiying Fang, Xiuchen Guo & Lina Zhao. (2023) Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment. Autoimmunity 56:1.
Read now
Read now
Guilherme Rossi Assis-Mendonça, Letícia Goulart Campos, Márcia Torresan Delamain, Angelo Borsarelli Carvalho de Brito, Marcello Ferreti Fanelli, Fernando Augusto Soares, Cármino Antônio de Souza, José Vassallo & Carmen Silvia Passos Lima. (2023) Association of single nucleotide variants in VEGFA and KDR with the risk and angiogenic features of diffuse large B-cell lymphoma. Leukemia & Lymphoma 0:0, pages 1-13.
Read now
Read now
Articles from other publishers (13)
Peter Borchmann, Jan-Michel Heger, Jörg Mahlich, Michael S. Papadimitrious, Sybille Riou & Barbara Werner. (2023) Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database. Journal of Cancer Research and Clinical Oncology 149:10, pages 7091-7101.
Crossref
Crossref
Bodo C. Melnik, Rudolf Stadler, Ralf Weiskirchen, Claus Leitzmann & Gerd Schmitz. (2023) Potential Pathogenic Impact of Cow’s Milk Consumption and Bovine Milk-Derived Exosomal MicroRNAs in Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences 24:7, pages 6102.
Crossref
Crossref
Peter Borchmann, Jan-Michel Heger, Jörg Mahlich, Michael S. Papadimitrious, Sybille Riou & Barbara Werner. (2022) Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis. Oncology and Therapy 11:1, pages 65-81.
Crossref
Crossref
Georg Hopfinger, Bernhard Rupp & Richard Greil. (2023) Barriers to patient access of CAR T cell therapies in Austria. memo - Magazine of European Medical Oncology 16:1, pages 79-90.
Crossref
Crossref
Michael Oertel, Christian Berdel, Gerhard Held, Klaus Herfarth, Heinz Schmidberger, Moritz Ernst, Georg Lenz, Peter Borchmann & Hans Theodor Eich. (2023) The new German evidence-based guideline on diffuse large B-cell lymphoma—key aspects for radiation oncologists. Strahlentherapie und Onkologie 199:2, pages 115-120.
Crossref
Crossref
Dhruv Sanjay Gupta, Vaishnavi Gadi, Ginpreet Kaur, Meena Chintamaneni, Hardeep Singh Tuli, Seema Ramniwas & Gautam Sethi. (2023) Resveratrol and Its Role in the Management of B-Cell Malignancies—A Recent Update. Biomedicines 11:1, pages 221.
Crossref
Crossref
Colin Thomas, Sameep Thapa, Connor McLaughlin, Molly Halloran & Pierluigi Porcu. (2023) Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma. Frontiers in Oncology 12.
Crossref
Crossref
Ismael Fernández-Miranda, Lucía Pedrosa, Marta Llanos, Fernando F. Franco, Sagrario Gómez, Paloma Martín-Acosta, Francisco R. García-Arroyo, Josep Gumá, Beatriz Horcajo, Ana K. Ballesteros, Laura Gálvez, Natividad Martínez, Miguel Marín, Silvia Sequero, Marta Navarro, Natalia Yanguas-Casás, Virginia Calvo, Antonio Rueda-Domínguez, Mariano Provencio & Margarita Sánchez-Beato. (2023) Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study. Clinical Cancer Research 29:1, pages 209-220.
Crossref
Crossref
Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera & Nikhil R. Thiruvengadam. (2022) Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood 140:25, pages 2697-2708.
Crossref
Crossref
Carlos Jiménez-Cortegana, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, Fernando Zapata, Natalia Palazón-Carrión, María L. Sánchez-León, Malika Tami, Antonio Pérez-Pérez, Flora Sánchez-Jiménez, Teresa Vilariño-García, Luis de la Cruz-Merino & Víctor Sánchez-Margalet. (2022) Obesity and Risk for Lymphoma: Possible Role of Leptin. International Journal of Molecular Sciences 23:24, pages 15530.
Crossref
Crossref
Jee H. Choe, Hisham Abdel-Azim, William V. Padula & Mohamed Abou-el-Enein. (2022) Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JAMA Network Open 5:12, pages e2245956.
Crossref
Crossref
Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Steve Serrao, Pejman Solaimani, Lihua Elizabeth Budde, Matthew G. Mei, Leslie L. Popplewell, Tanya Siddiqi, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera & Nikhil R. Thiruvengadam. (2022) Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood 140:19, pages 2024-2036.
Crossref
Crossref
Juan P. Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier L. Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin & Paolo F. Caimi. (2022) Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Advances 6:16, pages 4736-4739.
Crossref
Crossref